Clients receiving targeted therapy to treat cancer need to avoid which food?

A. Seasonal allergy only

Montelukast may be used for the treatment of allergic rhinitis associated with seasonal allergies, but its primary use is for asthma prevention.

B. Severe asthmatic attacks

Montelukast is not typically used for the treatment of severe asthmatic attacks. Short-acting bronchodilators and systemic corticosteroids are more commonly used in this scenario.

C. Acute bronchospasm

While montelukast has a role in the prevention of bronchospasm, it is not typically used for the acute treatment of bronchospasm. Short-acting bronchodilators are more appropriate for immediate relief of bronchospasm.

D. Maintenance and prevention of asthma

Montelukast (Singulair) is used for the maintenance and prevention of asthma. It is a leukotriene receptor antagonist that works by blocking the action of leukotrienes, which are inflammatory mediators involved in the pathophysiology of asthma. By inhibiting leukotrienes, montelukast helps to reduce airway inflammation and bronchoconstriction, thereby preventing asthma symptoms.

A. "The client’s degree of nausea."

The client's degree of nausea is a side effect of chemotherapy, but it is not a major obstacle to successful chemotherapy in the broader sense. Nausea can often be managed with antiemetic medications, and it is generally considered a manageable aspect of chemotherapy care.

B. "The patient’s reluctance about the doses administered."

Patient compliance and acceptance of the prescribed treatment are important factors in the success of chemotherapy. However, while patient reluctance can be a challenge, it is not considered a major obstacle to chemotherapy as there are strategies and interventions to address issues related to patient understanding, fears, or concerns.

C. "The toxicity of anticancer drugs to normal tissues."

This is the correct answer. The toxicity of anticancer drugs to normal tissues is a major obstacle in chemotherapy. While the drugs aim to kill rapidly dividing cancer cells, they can also affect healthy cells, leading to side effects and complications. Striking a balance between effective cancer treatment and minimizing harm to normal tissues is a key challenge in chemotherapy.

D. "The difficulty of maintaining venous access."

Maintaining venous access can be a logistical challenge in chemotherapy, but it is not considered a major obstacle to successful treatment. While it is important for delivering chemotherapy drugs, there are various methods and technologies to address issues related to venous access, such as the use of central venous catheters or ports.